V. 11. Therapeutic Toolbox

The microbiome's therapeutic toolbox is narrower than the shelves suggest: a probiotic only works when matched to strain, dose, and indication, FMT is the most powerful but strictly indicated, and a new generation of tools is arriving alongside them.

Chapters 3 and 10 told you where it's worth turning to the microbiota and what you can measure. This chapter answers the how — what tools we actually have, and when each is appropriate.

The market carries thousands of probiotic products, with "gut-friendly fiber," "enzyme complex," and "detox tea" standing on the pharmacy shelf alongside them. Clinical reality is much simpler: the number of effective tools is relatively small, and using them is indication- and strain-specific.

Probiotic selection — strain- and indication-specific

Per the WHO/ISAPP consensus, a "probiotic" is a live microorganism that, when consumed in adequate amounts, confers a well-defined health benefit. [561] Well-defined is the key — and exactly what's missing from most shelf products.

The table below summarizes evidence-based indications. Only these can be recommended responsibly.

What do the colors mean? Same system as in chapter 3.

How to shop for a probiotic

Six check points:

1. Strain name on label (not just genus). If absent, don't buy.
2. CFU value (colony-forming units) guaranteed at expiry (not at manufacture).
3. Refrigeration need — many sensitive strains (e.g., L. acidophilus) require refrigeration. Shelf-stable products aren't always trustworthy.
4. Match to indication — e.g., S. boulardii for AAD, B. infantis 35624 for IBS; not vice versa.
5. Course duration — most probiotics don't permanently engraft; maintenance effect requires continuous dosing. Don't expect a "restorative" miracle from a one-off course.
6. Product and manufacturer transparency — reputable makers document clinical trials and strain origin. A last-minute bargain purchase of a penny product is, at best, ineffective.

Prebiotic selection

Prebiotics are indigestible carbohydrates that reach the colon and feed your existing beneficial microbes. Six main groups are worth knowing.

1. Inulin and FOS (fructo-oligosaccharides) concentrate in chicory root, onion, garlic, and artichoke; they're Bifidobacterium-selective and effective at 5–10 g/day, but require gradual titration because they can cause bloating.
2. GOS (galacto-oligosaccharides) occur in legumes and breast milk, and are a common ingredient in infant formulas (2.5–8 g/day).
3. PHGG (partially hydrolyzed guar gum) — marketed as Sunfiber, Solgar — is particularly well tolerated in IBS, often better than inulin (5–10 g/day).

Beyond classical fibers, three additional groups deserve mention:

1. resistant starch (cooked-then-cooled rice or potato, green banana) boosts butyrate production;
2. beta-glucan (oats, barley) also has cholesterol-lowering effects;
3. polyphenol prebiotics (berries, cocoa, green tea) aren't classical fibers but their prebiotic activity is documented.

Synbiotics and postbiotics

The synbiotic is a simple idea: probiotic + prebiotic in one product. Two subcategories exist.

1. In complementary synbiotics, the two components act independently (e.g., L. rhamnosus GG + inulin),
2. while in synergistic synbiotics, the prebiotic specifically feeds the probiotic strain it accompanies (e.g., B. infantis + HMOs).

Synergistic versions are theoretically stronger, and their clinical evidence is growing — but they don't yet dominate the market.

The postbiotic concept differs: instead of delivering a live microbe, we deliver a microbial component or metabolite that exerts a health effect. This includes:

1. heat-killed probiotic strains — e.g., heat-killed B. lactis CECT 8145 studied for metabolic syndrome;
2. bacterial cell-wall components (lipoteichoic acid, peptidoglycan);
3. and directly administered microbial metabolites (butyrate salts, SCFA-salt formulations).

Postbiotic advantages: no live-bacteria risk (safe in immunocompromised patients), stable, longer shelf life. Disadvantage: clinical evidence is still building. [564]

FMT — Fecal microbiota transplantation

FMT^[G] transfers the stool microbiota of a healthy donor into the recipient colon. Our most powerful microbiota-directed tool: >85% cure rate in recurrent C. difficile infection.

Indications

FMT clinical indications group by the evidence tiers from chapter 3.

Proven, clinical practice: recurrent C. difficile infection (≥2 episodes) — the only indication where FMT is first/second-line therapy.

Investigational or in specialty centers: ulcerative colitis (4 positive RCTs, see chapter 3) and cancer immunotherapy-resistant melanoma (Davar 2021, Baruch 2021) — these can be performed within clinical protocols.

Research-only: Crohn's disease, IBS, autism, Parkinson's, metabolic syndrome — FMT here is acceptable within a clinical trial but doesn't yet have the professional grounding for first-line therapy. The "primum non nocere" principle is especially delicate for FMT — a nature-identical intervention that, by current knowledge, carries minimal risk: in therapy-resistant patients, denying a low-risk, potentially quality-of-life-improving therapy raises ethical questions of its own.

The procedure

1. Donor selection. Donors undergo strict screening: GI-symptom-free, blood and stool tests against a broad pathogen panel, normal BMI, and a verified drug history. The modern "superdonor" paradigm has been refined over the past 2 years: not the donor's health alone, but the donor–recipient microbiota compatibility may matter more. [565]
2. Preparation. Fresh or frozen suspension, or spore capsule. Modern preparations (Rebyota, Vowst) are standardized.
3. Delivery. Two main routes exist. The upper route runs via nasogastric tube, gastroscopy, or oral capsule; the lower route via colonoscopy or rectal enema. For C. difficile, both routes are effective, but the capsule method (Vowst, MicroBiome Bank, or custom-prepared) is most convenient for the patient.
4. Follow-up. Re-evaluation at 4–8 weeks. If recurrence occurs, a second FMT can be performed.

Safety and contraindications

FMT's safety profile is good but not zero risk. Reported complications: short-term mild GI symptoms (bloating, diarrhea), rarely infection (since the 2019 ESBL E. coli FDA case alert, donor screening has been stricter).

The contraindications span four main situations: severe immunodeficiency (relative, weigh carefully — after bone-marrow transplant it is already used in several centers); active GI bleeding; toxic megacolon; and severe acute illness, where the full procedure is too much of a burden.

Next-generation tools

Between FMT and classical probiotics a sharper middle ground is taking shape: defined-composition, controlled microbial preparations that aim to preserve the therapeutic power of whole-stool transfer without donor dependence. As of 2026, these tools are either in clinical trials or freshly FDA-approved (e.g., Rebyota and Vowst for C. difficile), but the therapeutic toolkit reaching market is set to reshape over the next five years. The subsections below cover synthetic consortia, live biotherapeutics, and phage therapy — with the current evidence status clarified for each.

Synthetic microbial communities (defined consortia)

The paradigm established by Vowst: we don't send the whole donor stool, only a selected, well-characterized microbial community. Pros: standardization, safer (less "everything from every donor"), industrially manufacturable. Cons: some efficacy may come from the full community's complexity.

Species-selective bacteriophages

Bacteriophages are viruses that infect only specific bacteria. Clinical applications: e.g., targeted adherent-invasive E. coli (AIEC) eradication in Crohn's — experimental phase. Also promising for antibiotic-resistant infections (compassionate use case reports).

Targeted prebiotics (custom oligosaccharides)

Carbohydrate structures that feed only specific bacterial species (e.g., only Akkermansia muciniphila or only F. prausnitzii). Experimental — promising in preclinical models.

Engineered probiotics (pharmabiotics)

Genetically modified bacteria with specific therapeutic function: e.g., insulin-like hormone-producing Lactococcus lactis for T1DM, or IL-10-secreting probiotic for IBD (ZyVersa, Synlogic platforms). Pre-FDA-approval; phase I/II clinical trials are underway.

The next 5–10 years

• Microbiome-mediated drug activation (digoxin and levodopa efficacy depend on microbial metabolism) is the most tangible direction for personalized prescribing.
• Microbiome-signature-based oncology prognostication and immunotherapy prediction is expected to enter routine clinical practice between 2027–2030.
• Standardized, manufactured FMT alternatives are developing — Vowst is the first, and additional products (CP101, VE303) are currently in phase III trials.
• Refined infant probiotic protocols — especially B. infantis restoration in premature and C-section-born infants — is the more scientific successor to "vaginal seeding."
• Finally, microbiome engineering: engineered probiotics for specific diseases (rheumatoid arthritis, metabolic syndrome, IBD).

What you cannot realistically expect within 10 years: the gray-level indications of chapter 3 (autism, Parkinson's, depression) entering clinical practice. Research advances, but translation to clinical protocols takes decades.

What you can do tomorrow

1. Starting an antibiotic course: S. boulardii CNCM I-745 500 mg/day or L. rhamnosus GG 10¹⁰ CFU/day, alongside the AB + 3 days after.
2. You have IBS symptoms: subtype-matched probiotic for a 4–8 week trial (see table), dietitian-supervised FODMAP, and ask your doctor about SIBO breath testing (see chapter 10).
3. You have recurrent C. difficile: ask your treating physician about FMT — available both at hospital level and in home-care settings in many EU countries.
4. You want general gut health: don't start with a probiotic; start with chapter 4 (diet) and chapter 5 (sleep–movement–stress). Probiotics are fine-tuning, not the foundation.

What's next

Part I (chapters 1–2) laid the foundations; Part II (3) the diseases; Part III (4–7) lifestyle; Part IV (8–9) life stages and genetics; Part V (10–11) diagnostics and therapy. Part VI (chapter 12) closes the book: a concrete action guide for four common profiles.

References

[36] Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017. Link

European consensus conference developing evidence-based recommendations on FMT for clinical practice, with 28 experts from 10 countries collaborating in working groups. Statements were generated through evidence-based review, evaluated electronically via a Delphi process, and finalized in a plenary consensus session. Recommendations cover FMT indications, donor selection, faecal material preparation, clinical management, faecal delivery, and minimum requirements for establishing an FMT centre. Provides the European standardization framework for safe and governed FMT delivery.

[561] Hill C, Guarner F, Reid G et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014. Link

An ISAPP expert panel convened in October 2013 reviewed the probiotic field 13 years after the original FAO/WHO definition. The panel affirmed the FAO/WHO definition — 'live microorganisms which when administered in adequate amounts confer a health benefit on the host' — as still relevant and sufficiently broad to accommodate current and anticipated applications. Inconsistencies between the FAO/WHO Expert Consultation Report and the FAO/WHO Guidelines were clarified in light of advances in science and use. The consensus statement promotes more precise use of the term 'probiotic' to help clinicians and consumers differentiate products on the market.

[562] Su GL, Ko CW, Bercik P et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020. Link

Su, Ko, Bercik and colleagues' 2020 Gastroenterology paper presents the American Gastroenterological Association (AGA) Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. The expert panel reviewed evidence across pouchitis, Clostridioides difficile infection, antibiotic-associated diarrhoea, IBS, IBD, acute infectious gastroenteritis (adults and children), and necrotising enterocolitis. The guideline conditionally recommends probiotics for selected indications (pouchitis prophylaxis: VSL#3; necrotising enterocolitis prevention: combination Lactobacillus + Bifidobacterium products), and recommends against probiotics for IBS, IBD induction/maintenance and acute infectious gastroenteritis in adults due to insufficient evidence. The guideline is the operative AGA reference for evidence-based probiotic use in GI disorders.

[563] Gibson GR, Hutkins R, Sanders ME et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017. Link

An ISAPP expert panel convened in December 2016 reviewed and updated the definition of prebiotics. Consistent with the original concept, the updated definition states that a prebiotic is 'a substrate that is selectively utilized by host microorganisms conferring a health benefit'. The expanded definition allows for non-carbohydrate substrates, applications beyond the gastrointestinal tract, and use in diverse non-food categories; the requirement for selective microbiota-mediated mechanisms is retained. Documented beneficial health effects are required, and the definition applies to both human and animal prebiotics.

[564] Salminen S, Collado MC, Endo A et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021. Link

An ISAPP panel in 2019 reviewed the increasingly used but inconsistently defined term 'postbiotic'. They defined a postbiotic as 'a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host'. Effective postbiotics must contain inactivated microbial cells or cell components, with or without metabolites, contributing to the observed health benefit. The panel discussed existing evidence for postbiotic health effects, proposed mechanisms of action, required levels of evidence, safety considerations and stakeholder implications.

[565] Wilson BC, Vatanen T, Cutfield WS, O'Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019. Link

FMT is highly effective for recurrent Clostridium difficile infection but its efficacy in chronic dysbiosis-associated diseases has been modest and variable. Multiple studies suggest FMT outcome depends on stool donor microbial diversity and composition, leading to the concept of FMT 'super-donors'. The review explores keystone species as predictors of FMT success and discusses how host genetics and diet may influence engraftment and maintenance — providing a framework for more targeted, donor-stratified bacteriotherapy.

[2714] Alang N, Kelly CR. Weight Gain After Fecal Microbiota Transplantation. Open Forum Infectious Diseases. 2015. Link

Case report of a previously normal-weight woman, successfully treated with FMT for recurrent Clostridioides difficile infection, who became obese over 16 months (BMI 26→33) after receiving stool from an overweight (related) donor. The case raised the possibility that a donor's metabolic phenotype is partly transferable to the recipient via the microbiota. A single case is not causal proof (other factors may have contributed), but it underscores the importance of donor selection and screening.